Karo Bio, Alkem sign dyslipidemia drug licensing deal
Under the agreement, Alkem will get commercialization rights for Karo Bio’s eprotirome across India and other countries in Asia-Pacific and Africa.. In connection to receive Indian marketing approval
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.